相关实验视频
Updated: Jun 26, 2025
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.2K
炎症性肠病中的生物标志物:一本实用指南
Jennie Clough1,2, Michael Colwill1, Andrew Poullis1
1St George's University Hospitals NHS Foundation Trust, London, UK.
Therapeutic advances in gastroenterology
|May 13, 2024
概括
像C反应蛋白和便calprotectin这样的生物标志物有助于评估炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩氏病.
科学领域:
- 胃肠病学和临床医学
- 生物标志物的发现和应用
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),对医疗保健造成重大负担,其全球流行率不断增加.
- 目前IBD的诊断和监测标准,主要是内镜手术,是侵入性的和昂贵的.
- 现有的非侵入性生物标志物,如C反应蛋白和便calprotectin,被广泛使用,但需要仔细解释.
研究的目的:
- 审查目前支持在管理UC和CD时使用已确定的生物标志物的证据.
- 为医疗保健专业人员提供关于解释IBD中的生物标志物数据的实际指导.
- 探索新生物标志物的潜力,以推进IBD的精准医学.
主要方法:
- 这项研究是对IBD生物标志物的现有文献进行叙事性审查.
- 总结了C-反应蛋白和便calprotectin在UC和CD中的临床功效的证据.
- 讨论了IBD生物标志物发现的未来方向.
主要成果:
- C-反应蛋白和便calprotectin是评估IBD活动和治疗反应的有价值,可访问的生物标志物.
- 对这些生物标志物的解释需要在临床表现的背景下考虑它们的局限性.
- 新兴的生物标志物显示出更个性化的IBD管理策略的前景.
结论:
- 生物标志物在IBD管理中为内镜提供了一个不那么侵入性和潜在的更具成本效益的补充.
- 优化当前生物标志物的使用和开发新的生物标志物对于改善患者的治疗结果至关重要.
- 生物标志物的进步是实现炎症性肠病精准医学目标的关键.
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166
01:30Inflammatory Bowel Disease II: Crohn's Disease
219
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
219
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
01:17Chronic Bowel Disorders: Introduction
445
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
445